View in EDS

Discovery, Optimization, and Biological Evaluation of Arylpyridones as Cbl-b Inhibitors.

Saved in:
Bibliographic Details
Title: Discovery, Optimization, and Biological Evaluation of Arylpyridones as Cbl-b Inhibitors.
Authors: Mfuh AM; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Boerth JA; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Bommakanti G; Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Chan C; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Chinn AJ; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Code E; Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Fricke PJ; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Giblin KA; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Gohlke A; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Hansel C; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Hariparsad N; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Hughes SJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Jin M; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Kantae V; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Kavanagh SL; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Lamb ML; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Lane J; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Moore R; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Puri T; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Quinn TR; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Reddy I; Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Robb GR; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Robbins KJ; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Gancedo Rodrigo M; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K.; Isomorphic Laboratories, 280 Bishopsgate, London EC2M 4RB, U.K., Schimpl M; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Singh B; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Singh M; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Tang H; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Thomson C; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Walsh JJ; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Ware J; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Watson IDG; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Ye MW; Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Wrigley GL; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Zhang AX; Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Zhang Y; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Grimster NP; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States.
Source: Journal of medicinal chemistry [J Med Chem] 2024 Jan 25; Vol. 67 (2), pp. 1500-1512. Date of Electronic Publication: 2024 Jan 16.
Publication Type: Journal Article
Journal Info: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1520-4804
DOI:10.1021/acs.jmedchem.3c02083